Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate (Q42993169)

12 November 2017

title

Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate (English)

1 reference

12 November 2017

1 reference

1 reference

P N Morcos

1

1 reference

12 November 2017

S A Moreira

2

1 reference

12 November 2017

B J Brennan

3

1 reference

12 November 2017

S Blotner

4

1 reference

12 November 2017

N S Shulman

5

1 reference

12 November 2017

P F Smith

6

1 reference

12 November 2017

publication date

14 June 2013

1 reference

European Journal of Clinical Pharmacology

12 November 2017

published in

1 reference

12 November 2017

volume

69

1 reference

12 November 2017

issue

10

1 reference

12 November 2017

page(s)

1777-1784

1 reference

Variability in drug metabolizing enzyme activity in HIV-infected patients

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Failure of critically ill patients to metabolise midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Regulation of drug metabolism and disposition during inflammation and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Altered theophylline pharmacokinetics during acute respiratory viral illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Altered elimination of antipyrine in patients with acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Noninvasive tests of CYP3A enzymes

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

21 January 2018

12 December 2020

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1525-5

Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture

21 January 2018

1 reference

12 December 2020

Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis

1 reference

12 December 2020

Theophylline toxicity and viral infections

1 reference

12 December 2020

Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes

1 reference

12 December 2020

Cyclosporine pharmacokinetics in anti-HCV+ patients

1 reference

12 December 2020

The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes

1 reference

12 December 2020

Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved

1 reference

12 December 2020

Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture

1 reference

12 December 2020

10.1007/S00228-013-1525-5

Identifiers

DOI

1 reference

12 November 2017

1 reference